News

• Prodotti competitors / Area HIV 29 maggio 2024

  Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

• Prodotti competitors / Area HIV 22 maggio 2024

  Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phas

• Prodotti competitors / Area Liver 18 marzo 2024

  EMA accepts for review the Marketing Authorization Application from CymaBay for Seladelpar for the treatment of Primary Biliary Cholangitis

• Prodotti competitors / Area HIV 8 marzo 2024

  HIV: Competitive Highlights at CROI 2024

• Prodotti competitors / Area Kite, Area Onco-Ema 8 dicembre 2023

  EU Conditionally Approves Pfizer’s ELREXFIO (elranatamab) for Relapsed & Refractory Multiple Myeloma

• Prodotti competitors / Area HIV 26 ottobre 2023

  Competitive Highlights at EACS 2023

• Prodotti competitors / Area HIV 18 ottobre 2023

  IDWeek 2023: Key Conference Themes and Highlights - HIV Treatment & Prevention

• Prodotti competitors / Area HIV 8 settembre 2023

  ViiV-sponsored new clinical trials to differentiate its products in portfolio and pipeline

• Prodotti competitors / Area Oncology 29 maggio 2023

  Ribociclib - Findings from the MAINTAIN study

• Prodotti competitors / Area Kite, Area Onco-Ema 6 marzo 2023

  Europe: Oncology CHMP Minutes for December 2022